- Obese men with melanoma or skin cancer have a better survival rate than those with a normal BMI.
- Usually, women are at a lower risk due to the increased production of estrogen that responds well to immunotherapy that helps kill cancer cells.
- Obese men also have high levels of estrogen as the adipose tissue converts androgens to estrogens and poses the same effect to immunotherapy.
Targeted or immune therapies improve the survival rate of obese men with metastatic melanoma.
This effect, referred to as the "Obesity Paradox", principally manifested itself in men, said Jennifer McQuade, M.D., lead author.
"Obese men consistently did much better than men with a normal BMI, with nearly a doubling of overall survival," McQuade said. The researchers found no significant differences in survival between women with normal, overweight or obese BMI.
Women with metastatic melanoma have long been known to have better outcomes compared to men, McQuade noted. In this study obesity overcame that survival disadvantage for men, leading researchers to now look at the possible impact of sex hormones in this effect.
How Does Obesity Increase Survival Rate?
The relationship between obesity and survival in patients that already have cancer is not as consistent. Recent studies have shown a similar survival benefit for obese patients with colorectal or kidney cancer.
Associations don't prove causation, the researcher's note, but point to new areas to study in greater depth. "The public health message is not that obesity is good. Obesity is a proven risk factor for many diseases," McQuade said. "Even within our metastatic melanoma population, we would not suggest that patients intentionally gain weight. We need to figure out what is driving this paradox and learn how to use this information to benefit all of our patients."
The team expected to find obesity to be harmful for melanoma patients, based in part on research that implicates obesity in activation of a cancer-promoting molecular pathway called IGF-1/PI3K/AKT.
They analyzed the association between body mass index (weight divided by height) and progression-free survival (PFS) and overall survival (OS) in six independent cohorts of patients treated with targeted therapy, immunotherapy or chemotherapy in pivotal trials that led to FDA approval of these drugs.
While advantages in PFS and OS emerged in an overall meta-analysis of the entire group, the survival benefit associated with obesity was restricted to men treated with targeted or immunotherapies, where obese men had a 47 percent decreased risk of death compared to men with normal BMI.
Overall survival in men
The results from 599 patients receiving combination targeted therapy of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) show that :
- Those with normal BMI of 18.5-24.9kg/m2 had a PFS of 9.6 months, OS of 19.8 months.
- Those who are obese with a BMI 30 and above had a PFS of 15.7 months, OS of 33.0 months.
- Even after including factors such as age, sex, stage, disease burden, certain mutations and prior treatment showed that obesity still improved PFS and OS compared to normal BMI patients.
- By contrast, women, for example, had overall median survival of at least 33 months, regardless of BMI.
Obesity is associated with increased inflammation, which could improve the effectiveness of checkpoint blockade drugs that unleash an immune response against cancer.
The sex-specificity of the observed differences points to a potential hormonal mediator. Fat (adipose) tissue produces an enzyme called aromatase that converts male hormones called androgens into estrogens, female hormones. Perhaps this happens enough in obese men to help them clear some type of hurdle toward greater survival, McQuade said.
The researchers are collaborating with investigators at the University of Pennsylvania that have found that turning on a very specific type of estrogen receptor on melanoma makes it vulnerable to immunotherapy.
The MD Anderson team also is looking at gene expression, mutations and immune profiling to identify potential differences in melanoma in obese and non-obese patients and developing preclinical models.
Please use one of the following formats to cite this article in your essay, paper or report:
Julia Samuel. (2018, February 13). Obesity Prolongs Life For Men With Metastatic Melanoma. Medindia. Retrieved on Aug 08, 2022 from https://www.medindia.net/news/healthwatch/obesity-prolongs-life-for-men-with-metastatic-melanoma-176968-1.htm.
Julia Samuel. "Obesity Prolongs Life For Men With Metastatic Melanoma". Medindia. Aug 08, 2022. <https://www.medindia.net/news/healthwatch/obesity-prolongs-life-for-men-with-metastatic-melanoma-176968-1.htm>.
Julia Samuel. "Obesity Prolongs Life For Men With Metastatic Melanoma". Medindia. https://www.medindia.net/news/healthwatch/obesity-prolongs-life-for-men-with-metastatic-melanoma-176968-1.htm. (accessed Aug 08, 2022).
Julia Samuel. 2021. Obesity Prolongs Life For Men With Metastatic Melanoma. Medindia, viewed Aug 08, 2022, https://www.medindia.net/news/healthwatch/obesity-prolongs-life-for-men-with-metastatic-melanoma-176968-1.htm.